Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans.
Where this comes from
- Record sourced from PubMed, PMID 28903137.
- Also identified by DOI 10.1001/jamacardio.2017.3051 and PMC identifier 5815006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study examines PCSK9i cost-sharing requirements for Medicare Part D plans nationwide, which insure 41 million beneficiaries.
Medical subject headings
- Antibodies, Monoclonal
- Anticholesteremic Agents
- PCSK9 Inhibitors